EUVIMEDEUVIMED entdecken
Open Access

Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma

Marie Ménard iD, Hiroyuki Yoda iD, Nicole Nasholm iD, Megumi J Barata iD, Linyu Wang iD, Erin F Simonds iD, Edbert D Lu iD, Shannon Wong-Michalak iD, Lauren McHenry iD, Alvin Farrel iD, Rebecca Kaufman iD, Vanessa Lopez iD und 8 weitere

Journal of Experimental Medicine · 01.09.2025 · 222 (9)

DOI: 10.1084/jem.20231417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 14.07.2025. Verfasst von Marie Ménard und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Immunotherapy, Myeloid Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: St. Baldrick's Foundation, Uehara Memorial Foundation, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroblastomas are highly heterogeneous tumors originating from neural crest-derived cells destined to form the sympathetic nervous system. Nearly half of high-risk tumors present with amplification of the MYCN proto-oncogene. Here, we describe a Mycn-driven, transplantable, non-germline, genetically engineered mouse model (Mycn-nGEMM). Mycn-nGEMM tumors recapitulate the immune-evasive, macrophage-rich tumor microenvironment of high-risk, MYCN-amplified human neuroblastoma. Treatment of tumor-bearing mice with anti–PD-L1, but not anti-PD-1 or anti-CTLA-4, inhibited tumor growth, profoundly remodeling the tumor microenvironment by depleting anti-inflammatory macrophages and increasing T cell infiltration. Surprisingly, while tumor cells showed low expression of PD-L1, anti-inflammatory macrophages from both murine and human neuroblastoma expressed PD-L1. We identified cytokines, including macrophage migration inhibitory factor, secreted by the Mycn-nGEMM cancer cells that drive expression of PD-L1 on macrophages. Combining anti–PD-L1 with CD40 agonist antibodies further improved survival in Mycn-nGEMM mice, demonstrating the potential for myeloid-targeting immunotherapies to overcome inhibitory barriers in immune-evasive neuroblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaImmunotherapyMyeloid CellsAnimalsHumansMiceProto-Oncogene MasN-Myc Proto-Oncogene ProteinTumor MicroenvironmentB7-H1 AntigenMacrophagesCell Line, TumorMice, TransgenicDisease Models, AnimalCD40 Antigens

Substanzen

Proto-Oncogene MasN-Myc Proto-Oncogene ProteinMAS1 protein, humanB7-H1 AntigenCD40 Antigens

Autor:innen und Institutionen

  • Department of Neurology, University of California, San Francisco, CA, USA.
  • Helen Diller Family Comprehensive Cancer Center, University of California , San Francisco, CA, USA.
  • Department of Pediatrics, University of California, San Francisco, CA, USA.
  • Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Department of Biomedical and Health Informatics and Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Children's Hospital Los Angeles, Cancer and Blood Disease Institutes, and The Saban Research Institute , Los Angeles, CA, USA.

ORCID-Profile: Marie Ménard, Hiroyuki Yoda, Nicole Nasholm, Megumi J Barata, Linyu Wang, Erin F Simonds, Edbert D Lu, Shannon Wong-Michalak, Lauren McHenry, Alvin Farrel, Rebecca Kaufman, Vanessa Lopez, Rebekah J Kennedy, G Esteban Fernandez, Hiroyuki Shimada, Liron D Grossmann, Shahab Asgharzadeh, John M Maris, W Clay Gustafson, William A Weiss

Förderung

  • St. Baldrick's Foundation
  • Uehara Memorial Foundation
  • NIH HHS
  • Alex's Lemonade Stand Foundation
  • U.S. Department of Defense
  • NINDS NIH HHS
  • National Cancer Center
  • Cancer Research UK

Zitieren

APA

Ménard, M., Yoda, H., Nasholm, N., Barata, M. J., Wang, L., Simonds, E. F., Lu, E. D., Wong-Michalak, S., McHenry, L., Farrel, A., Kaufman, R., Lopez, V., Kennedy, R. J., Fernandez, G. E., Shimada, H., Grossmann, L. D., Asgharzadeh, S., Maris, J. M., Gustafson, W. C., & Weiss, W. A. (2025). Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma. Journal of Experimental Medicine, 222(9). https://doi.org/10.1084/jem.20231417

Vancouver

Ménard M, Yoda H, Nasholm N, Barata MJ, Wang L, Simonds EF, et al. Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma. Journal of Experimental Medicine. 2025;222(9). doi:10.1084/jem.20231417

BibTeX
@article{Mnard2025,
  author = {Ménard, Marie and Yoda, Hiroyuki and Nasholm, Nicole and Barata, Megumi J and Wang, Linyu and Simonds, Erin F and Lu, Edbert D and Wong-Michalak, Shannon and McHenry, Lauren and Farrel, Alvin and Kaufman, Rebecca and Lopez, Vanessa and Kennedy, Rebekah J and Fernandez, G Esteban and Shimada, Hiroyuki and Grossmann, Liron D and Asgharzadeh, Shahab and Maris, John M and Gustafson, W Clay and Weiss, William A},
  title = {Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma},
  journal = {Journal of Experimental Medicine},
  year = {2025},
  volume = {222},
  number = {9},
  doi = {10.1084/jem.20231417}
}
Kostenlos starten →